Incheon City Takes off as Culture and Tourism Industry Hub in Northeast Asia with IFEZ’s Yeongjong Resort Complex Cluster
With rich tourism infrastructure and resources, including the world’s top-level Incheon International Airport, Ganghwa Island, open port area, and multiple islands, the Incheon Metropolitan City government plans to take off as a hub of culture and tourism industry in Northeast Asia through the Yeongjong-do Integrated Resort Cluster Project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005029/en/
Incheon City plans to take off as a hub of culture and tourism industry in Northeast Asia through the Yeongjong-do Integrated Resort Cluster Project. Yeongjong International Town, where the Incheon International Airport is located, continues to expand cultural and tourism facilities. The first resort complex in Korea, the Paradise City comprises a 5-star hotel, the largest foreigners-only casino in Korea, and a convention hall that can accommodate 1,600 persons opened in 2017. To open it in 2021, the Caesars Resort Complex is under construction in Yeongjong-do by Caesars Entertainment. It will consist of a luxury hotel with over 700 rooms, casino for foreigners only, convention facilities, live entertainment performing hall, signature spa and a swimming pool. Adjacent to the Incheon International Airport, the Inspire Resort Complex is under construction led by Mohegan Gaming and Entertainment to open in 2022. (Photo: Business Wire)
Yeongjong International Town, where the Incheon International Airport is located, continues to expand cultural and tourism facilities, such as luxurious 5-star hotels, foreigners-only casinos, convention installations, spas, theme parks and more.
Having opened in April 2017 as the first resort complex in Korea, the ‘Paradise City’ comprises a 5-star hotel with 711 rooms, the largest foreigners-only casino in Korea, and a convention hall that can accommodate 1,600 persons. From September 2018, it has been operating a boutique hotel with 58 suite rooms, spa blended with Korean dry sauna culture, the largest recreation club in Northeast Asia, and an art exhibition space. In March 2019, it opened the Wonder Box, an indoor theme park with the concept of ‘amusement park in the evening’, presenting enjoyment both to foreign and local visitors.
To open it in 2021, the Caesars Resort Complex is under construction in Yeongjong-do by Caesars Entertainment headquartered in Las Vegas. The Caesars Resort Complex will consist of a luxury hotel with over 700 rooms, casino for foreigners only, convention facilities, live entertainment performing hall, signature spa and a swimming pool.
Adjacent to the Incheon International Airport, the Inspire Resort Complex is under construction led by Mohegan Gaming and Entertainment (MGE), the owner of Mohegan Sun casino located in Connecticut, to open in 2022. The resort complex will include a luxury hotel with over 1,250 rooms, foreigners-only casino, and indoor and outdoor theme parks. It will also operate a performing facility (arena) that can accommodate 15,000 audiences, staging Las Vegas-level fantastic performances all year round. It is expected to significantly contribute to spreading the Korean Wave.
The Incheon Free Economic Zone Authority expects the resort complex businesses to generate over 20,000 new jobs and production inducement effect of approximately KRW2 trillion (USD1680 million) annually. It also expects that the resort complex industry will conspicuously contribute to invigorating the regional economy and development of the MICE industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005029/en/
Contact information
Incheon Metropolitan City
Sang Kon Park
+82 32-440-3052
sangkon7@korea.kr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi ® /Minjuvi ® ) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 14:30:00 EET | Press release
Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years of age, or age-adjusted IPI (aaIPI) of two to three (2-3) for patients ≤60 years of age. The trial met its primary endpoint of progression-free survival (PFS) by investigator assessment (Hazard Ratio 0.75 [0.59,0.96]; p-value 0.019), according to Lugano 2014 criteria. The trial also met its key secondary endpoint of event-free survival (EFS) by investigator assessment. No new safety signals were observed. “The frontMIND stud
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 14:30:00 EET | Press release
Cybin Inc. (the “Company”) doing business as Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (“Helus Pharma”), a clinical stage pharmaceutical company committed to helping minds heal by developing NSAs, today announced that the Company will operate under the business name Helus Pharma (pronounced “Heal-Us”) and trade on Nasdaq with ticker symbol HELP. “Our new business name more accurately describes our compounds and reflects our anticipated transformation from a global clinical stage discovery and development company to a commercial-ready pharmaceutical company, with our two lead candidates HLP003 and HLP004,” said Eric So, interim chief executive officer of the Company. “Over the past several years, we have advanced our pipeline portfolio of differentiated, proprietary NSA drug candidates, which includes over 350 filed patents with more than 100 already granted. We are approaching the commercialization of HLP003 with strong clinical data and significant market potential, subject to the
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 14:00:00 EET | Press release
Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV. “This is an important milestone toward our goal of addressing critical gaps that patients living with polycythemia vera face today,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “The comprehensive VERIFY study data underscore rusfertide’s strong clinical profile and potential to provide sustained hematocrit control while reducing phlebotomy and symptom burden. Our collaboration with Protagonist exemplifies how partnerships can advance innovative science, with a focus on m
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance with a Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 14:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Macnica Appoints Sebastien Dignard as CEO of Atlantic Region to Accelerate Global Component-to-Solutions and Vertical Strategy5.1.2026 13:00:00 EET | Press release
Macnica Inc. today announced the promotion of Sebastien Dignard to chief executive officer of the company’s Atlantic region. In this role, Dignard will lead Macnica’s business across North America, Europe and South America, accelerating the company’s component-to-solutions strategy and strengthening cross-regional collaboration to deliver long-term value for customers and partners across key verticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105529342/en/ Sebastien Dignard, CEO, Macnica Atlantic Region Dignard previously served as president of Macnica Americas for two years where he led the organization through a period of growth and transformation across semiconductors, imaging, networking and advanced technologies. Under his leadership, the company shifted from a focus on individual components to value-driven solutions, ecosystem partnerships and customer-centric execution across key vertical markets. Dignard wil
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom